Alexion Broadens and Strengthens its Executive Leadership Team

  Alexion Broadens and Strengthens its Executive Leadership Team

        Martin Mackay, Ph.D. to Join Alexion as Global Leader of R&D;
         Saqib Islam To Join as Chief Strategy and Portfolio Officer

 Stephen Squinto, Ph.D., Promoted to New Position of Chief Global Operations

Business Wire

CHESHIRE, Conn. -- April 25, 2013

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it is
broadening and strengthening its executive leadership team in line with the
Company’s expanding global mission to develop and commercialize life
transforming therapies for patients with disorders that are severe,
life-threatening, and ultra-rare.

Stephen Squinto, Ph.D., co-founder of Alexion, is being promoted to the newly
created position of Executive Vice President, Chief Global Operations Officer.
Martin Mackay, Ph.D. will be joining Alexion as Executive Vice President,
Global Head of R&D, and Saqib Islam, J.D. has joined Alexion as Senior Vice
President, Chief Strategy and Portfolio Officer. All three executives will
report directly to Leonard Bell, M.D., Chief Executive Officer of Alexion.

The arrivals of Dr. Mackay and Mr. Islam will help to broaden Alexion’s
portfolio of transformative ultra-orphan therapeutic candidates and accelerate
the development of these candidates into approved products. The promotion of
Dr. Squinto to his new position will support these initiatives, and also
improve and expand critical processes in manufacturing, quality and corporate
project management.

Growing to Serve More Patients, with More Disorders, in More Countries

Alexion currently serves patients in nearly 50 countries with Soliris®
(eculizumab), the Company’s first approved product. Soliris is approved for
patients with paroxysmal nocturnal hemoglobinuria (PNH) in the US, European
Union, Japan and other territories as the first and only treatment indicated
for this debilitating and life-threatening ultra-rare blood disease. Soliris
is also approved for patients with atypical hemolytic uremic syndrome (aHUS)
in the US and European Union as the first and only treatment indicated for
this life-threatening and ultra-rare, genetic disease. As it continues the
global introductions of Soliris in PNH and aHUS, the Company is developing the
most robust pipeline in its history, with five highly innovative therapeutic
candidates at various stages of development across nine severe and
life-threatening disorders that are also ultra-rare.

Stephen Squinto, Ph.D.

Dr. Squinto, co-founder of Alexion along with Dr. Bell, has helped to grow the
Company from a start-up to a global organization with 1,500 employees around
the world. Dr. Squinto continues to serve as a key member of the executive
leadership team, having risen to Executive Vice President and Head of R&D in
2007, and subsequently leading the development of Soliris through its approval
in aHUS. Most recently, Dr. Squinto has driven the expansion of Alexion’s R&D
pipeline to now comprise five highly innovative therapeutic candidates. In his
new position of Chief Global Operations Officer, Dr. Squinto will increasingly
focus his activities on leadership of the Company’s critical technical
operations and quality organizations. Dr. Squinto will commence his new duties
at Alexion in mid-May.

“Steve’s deep experience, strong technical background and excellent leadership
skills, position him well to lead the critical expansions in our global
manufacturing and quality organizations,” said Dr. Bell. “Additionally,
Steve’s leadership in the development of a corporate project management
organization will serve as a critical underpinning for our global growth
across many vital functions and projects.”

Martin Mackay, Ph.D.

Dr. Mackay brings to Alexion more than 30 years of experience in drug
discovery and development on a global scale. In his position, Dr. Mackay will
focus on continuing to build and improve Alexion’s global research and
development organization with a goal of accelerating the simultaneous
development of multiple drug candidates in debilitating and life-threatening
ultra-rare disorders across a range of therapeutic areas. Most recently, Dr.
Mackay served as President, Research and Development at AstraZeneca, reporting
directly to the CEO, where he led all R&D functions on a global basis,
including discovery research, clinical development, regulatory affairs and key
related R&D functions. Prior to AstraZeneca, Dr. Mackay held positions of
increasing responsibility at Pfizer, rising to the position of President, Head
of Pfizer Pharmatherapeutics, R&D, where he reported to the CEO and Chairman,
overseeing all aspects of discovery and development of therapies across nine
therapeutic areas. Earlier in his career, Dr. Mackay worked in the CIBA
organization (now Novartis) and held positions within academia. He received
his Ph.D. in molecular genetics from the University of Edinburgh, Scotland.
Dr. Mackay will join Alexion in mid-May.

“I am excited to be joining Alexion at a time when the company is developing
the most robust pipeline in its history. With an exclusive focus on
transformative therapies, we can bring hope to an increasing number of
patients with a wide range of life-threatening ultra-rare disorders,” said Dr.

“Martin’s passion to help patients, and his world-class experience in building
and leading talented R&D organizations across multiple therapeutic areas, will
help Alexion to reach the next levels in our mission to bring additional
breakthrough therapies to individuals and families suffering from devastating
and ultra-rare conditions,” said Dr. Bell.

Saqib Islam

Mr. Islam brings to Alexion 18 years of experience in global business
management, with a focus on business development, strategic decision-making
and planning, and capital markets. In his new position, he will focus on both
executing our corporate growth strategies as well as contributing to our
assessment and management of our global operations. Mr. Islam has an extensive
background in the healthcare banking sector, having held positions of
increasing responsibility in the investment banking divisions of Merrill
Lynch, Morgan Stanley, and most recently, Credit Suisse Securities, where he
served as Managing Director, Head of Healthcare and Diversified Industrials
Capital Markets. Earlier in his career, at The Boston Consulting Group, Mr.
Islam had provided strategic analysis and advice to client firms across
diverse industry segments. Mr. Islam received his Bachelor’s degree from
McGill University and his J.D. from Columbia Law School.

“Alexion offers an unmatched combination of a unique and highly respected
track record within the ultra-orphan space, substantial global resources, and
an entrepreneurial determination to serve even more patients with severe,
ultra-rare disorders,” said Mr. Islam. “I look forward to helping Alexion to
continue growing into a leadership position on the global healthcare stage.”

“Saqib’s experience within healthcare and across other key industries will be
invaluable as we enter the next phase of leading the Alexion organization to
maximize our opportunities to serve patients,” said Dr. Bell. “He will play a
central role as we continue to grow our global organization to serve more
patients with additional severe and ultra-rare disorders.”

About Soliris

Soliris is a first-in-class terminal complement inhibitor developed from the
laboratory through regulatory approval and commercialization by Alexion.
Soliris is approved in the U.S., European Union, Japan and other countries as
the first and only treatment for patients with paroxysmal nocturnal
hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood
disorder, characterized by complement-mediated hemolysis (destruction of red
blood cells). Soliris is indicated to reduce hemolysis.

Soliris is also approved in the U.S. and the European Union as the first and
only treatment for patients with atypical hemolytic uremic syndrome (aHUS), a
debilitating, ultra-rare and life-threatening genetic disorder characterized
by complement-mediated thrombotic microangiopathy, or TMA (blood clots in
small vessels). Soliris is indicated to inhibit complement-mediated TMA. The
effectiveness of Soliris in aHUS is based on the effects on TMA and renal
function. Prospective clinical trials in additional patients are ongoing to
confirm the benefit of Soliris in patients with aHUS. Soliris is not indicated
for the treatment of patients with Shiga toxinE. colirelated hemolytic
uremic syndrome (STEC-HUS).

Alexion's breakthrough approach in complement inhibition has received the
pharmaceutical industry's highest honors: the 2008 Prix Galien USA Award for
Best Biotechnology Product with broad implications for future biomedical
research, and the 2009 Prix Galien France Award in the category of Drugs for
Rare Diseases. More information, including the full prescribing information on
Soliris, is available

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on
serving patients with severe and ultra-rare disorders through the innovation,
development and commercialization of life-transforming therapeutic products.
Alexion is the global leader in complement inhibition and has developed and
markets a treatment for patients with PNH and aHUS, two debilitating,
ultra-rare and life-threatening disorders caused by chronic uncontrolled
complement activation. The treatment is currently approved in more than 40
countries for the treatment of PNH, and in the United States and the European
Union for the treatment of aHUS. Alexion is evaluating other potential
indications for its marketed drug and is developing four other highly
innovative biotechnology product candidates, which are being investigated
across nine severe and ultra-rare disorders beyond PNH and aHUS. This press
release and further information about Alexion Pharmaceuticals, Inc. can be
found at:

Safe Harbor Statement

This news release contains forward-looking statements. Forward-looking
statements are subject to factors that may cause Alexion's results and plans
to differ from those expected, including for example, decisions of regulatory
authorities regarding marketing approval or material limitations on the
marketing of Soliris for its current or potential new indications, and a
variety of other risks set forth from time to time in Alexion's filings with
the Securities and Exchange Commission, including but not limited to the risks
discussed in Alexion's Quarterly Report on Form 10-K for the period ended
December 31, 2012, and in Alexion's other filings with the Securities and
Exchange Commission. Alexion does not intend to update any of these
forward-looking statements to reflect events or circumstances after the date
hereof, except when a duty arises under law.



Alexion Pharmaceuticals, Inc.
Irving Adler, 203-271-8210
Executive Director,
Corporate Communications
Rx Communications (Investors)
Rhonda Chiger, 917-322-2569
Press spacebar to pause and continue. Press esc to stop.